tumor cell dissemination
Recently Published Documents


TOTAL DOCUMENTS

114
(FIVE YEARS 24)

H-INDEX

26
(FIVE YEARS 4)

2021 ◽  
Vol 50 (3) ◽  
pp. 28-30
Author(s):  
A. F. Urmancheeva ◽  
D. R. Zel'dovich ◽  
M. S. Shushania ◽  
A. V. Safronov

Peritoneal cytological investigation was carried out inpatients with endometrial cancer, who were subjected to hysteroscopy before the operation (37patients) or were operated on without hysteroscopy. Comparative analysis of the data didnt reveal the role of hysteroscopy in tumor cell dissemination.


Author(s):  
E. V. Slukhanchuk ◽  
V. O. Bitsadze ◽  
J. Kh. Khizroeva ◽  
M. V. Tretyakova ◽  
A. G. Solopova ◽  
...  

It has long been recognized a crucial role played by platelets in thrombosis and hemostasis. Along with that, laboratory and clinical data suggest that platelets contribute to tumor progression and metastasis through a variety of interactions with cancer cells. During oncological process, the platelet function becomes modulated via their activation and increased aggregation being one of the risk factors for developing thrombosis in cancer patients. The platelets per se enhance tumor cell dissemination, activate endothelial cells, and attract immune cells to the primary and metastatic tumor sites. In this review, we summarize the current knowledge about the complex interactions between platelets and tumor cells, as well as cells of the microenvironment, and discuss the development of new antitumor agents aimed at various arms in platelet functioning.


2021 ◽  
Author(s):  
Xiaoxiao Guo ◽  
Jodie R. Malcolm ◽  
Anjana Patel ◽  
Marrwa M. Ali ◽  
Goreti Ribeiro Morais ◽  
...  

2020 ◽  
Vol 80 (18) ◽  
pp. 3867-3879 ◽  
Author(s):  
David C. Benjamin ◽  
Joon Ho Kang ◽  
Bashar Hamza ◽  
Emily M. King ◽  
John M. Lamar ◽  
...  

2020 ◽  
Vol 11 (7) ◽  
pp. 3633 ◽  
Author(s):  
Jessica E. Fitzgerald ◽  
Brook K. Byrd ◽  
Roshani A. Patil ◽  
Rendall R. Strawbridge ◽  
Scott C. Davis ◽  
...  

2020 ◽  
Vol 26 (7) ◽  
pp. 1147-1147
Author(s):  
Francesca Chemi ◽  
◽  
Dominic G. Rothwell ◽  
Nicholas McGranahan ◽  
Sakshi Gulati ◽  
...  

2020 ◽  
Vol 22 (7) ◽  
pp. 955-966 ◽  
Author(s):  
Justine Münsterberg ◽  
Desirée Loreth ◽  
Laura Brylka ◽  
Stefan Werner ◽  
Jana Karbanova ◽  
...  

Abstract Background Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis. The aim of our study was to investigate the role of activated leukocyte cell adhesion molecule (ALCAM) in BM formation in NSCLC. Methods Immunohistochemical analysis was performed on 143 NSCLC primary tumors and BM. A correlation between clinicopathological parameters and survival was developed. Biological properties of ALCAM were assessed in vitro by gene ablation using CRISPR/Cas9 technology in the NCI-H460 NSCLC cell line and in vivo by intracranial and intracardial cell injection of NCI-H460 cells in NMRI-Foxn1nu/nu mice. Results ALCAM expression was significantly upregulated in NSCLC brain metastasis (P = 0.023) with a de novo expression of ALCAM in 31.2% of BM. Moderate/strong ALCAM expression in both primary NSCLC and brain metastasis was associated with shortened survival. Functional analysis of an ALCAM knock-out (KO) cell line showed a significantly decreased cell adhesion capacity to human brain endothelial cells by 38% (P = 0.045). In vivo studies showed significantly lower tumor cell dissemination in mice injected with ALCAM-KO cells in both mouse models, and both the number and size of BM were significantly diminished in ALCAM depleted tumors. Conclusions Our findings suggest that elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. Key Points 1. ALCAM expression associates with poor prognosis and brain metastasis in NSCLC. 2. ALCAM mediates interaction of NSCLC tumor cells with brain vascular endothelium. 3. ALCAM might represent a novel preventive target to reduce the occurrence of BM in NSCLC.


Sign in / Sign up

Export Citation Format

Share Document